Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Set Alert for Commercial

J.P. Morgan Stockwatch: No Substitute For M&A

Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.

 

M & A Advisory Committees StartUps and SMEs

Piramal Profits As It Sheds DRG To Clarivate For $950m

An experienced hand at M&A, Ajay Piramal has done it again – this time selling Decision Resources Group to Clarivate Analytics for $950m. Apart from $900m in cash, Piramal Enterprises will get a stake in Clarivate while the latter expects the acquisition to be earnings-accretive in 2020.

Commercial M & A Strategy

Companies

Set Alert for Companies

Latest From Companies

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Leadership Business Strategies

Decade In Review: C-Suite Shifts At Family-Owned Indian Firms

Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.

India Commercial

Amgen To Buy Out Japan JV With Astellas

Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.

Japan Deals

J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara

A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.

Sales & Earnings Business Strategies

AstraZeneca Pledges To Become Carbon-Negative By 2030

AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.

Companies Manufacturing

Novo Executive Calls For ‘Real AMR Action’ In Davos

The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.

Companies Research & Development
See All

Deals

Set Alert for Deals

Latest From Deals

Finance Watch: 2019 Ended With Near-Record VC Financings, But Some Slowing Expected In 2020

Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.

Financing Innovation

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Leadership Business Strategies

Finance Watch: Expect A Busy First Half For 2020 IPOs

Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.

Financing Business Strategies

Amgen To Buy Out Japan JV With Astellas

Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.

Japan Deals

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Deals Business Strategies

BioNTech Bags Bargain With Neon Buy

Neon listed on the NASDAQ at $16 per share 18 months ago. It has now been picked up by the ambitious German biotech for just $2.18 per share, having recently ended its cancer vaccine programs and laid off a quarter of its workforce.

M & A ImmunoOncology
See All

Strategy

Set Alert for Strategy

Latest From Strategy

Novartis Q4 Preview: Launches Likely To Deliver

Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.

Sales & Earnings Strategy

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

Business Strategies Companies

J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More

Additional highlights from the J.P. Morgan Healthcare Conference, including Takeda’s partnering outlook, Sage’s guidance on Zulresso sales, Frequency’s next steps for its hearing loss drug and Revance’s preparations to take on the aesthetics market. 

Business Strategies Artificial Intelligence

Recordati's Isturisa Approved For Cushing's In EU

Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.

Approvals Rare Diseases

J.P. Morgan Notebook Day 3: Skyrizi Momentum Builds, What's Next For Amarin, Viatris Debuts And More

Daily round-up from the J.P. Morgan Healthcare Conference in San Francisco: AbbVie's Skyrizi takes psoriasis lead, Amarin goes it alone, Viatris debuts, BeiGene on US drug pricing and Roche think neuroscience is the new oncology.

Business Strategies Launches

Interview: KaNDy Menopause Therapy Hits Sweet Spot

Prospective partners will be impressed by data which shows that the UK company's once-daily oral treatment reduces hot flashes and night sweats and has also shown very rapid improvements in mood and sleep.

Clinical Trials Metabolic Disorders
See All

Market Access

Set Alert for Market Access

Latest From Market Access

After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal

Tagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.
Commercial United Kingdom

Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status

Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.

Market Intelligence Launches

Fewer US Market Access Restrictions For Branded I&I Drugs Will Drive Growth

Access to branded drugs has remained steady, but there has been less management across brands by commercial payers, according to an analysis of the I&I market access environment by Bernstein.

Market Access Inflammation
See All

Market Intelligence

Set Alert for Market Intelligence

Latest From Market Intelligence

Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status

Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.

Market Intelligence Launches

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

Business Strategies Companies

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Cancer Health Technology Assessment
See All
UsernamePublicRestriction

Register